Advances in Molecular Biology and Targeted Therapy of Mantle Cell Lymphoma
1
First Dept. of Medicine-Hematology, General University Hospital in Prague, 128 08 Prague, Czech Republic
2
Institute of Pathological Physiology, First Faculty of Medicine, Charles University, 128 53 Prague, Czech Republic
Int. J. Mol. Sci. 2019, 20(18), 4417; https://doi.org/10.3390/ijms20184417
Received: 15 August 2019
/
Revised: 2 September 2019
/
Accepted: 4 September 2019
/
Published: 8 September 2019
(This article belongs to the Special Issue Advances in Molecular Biology and Targeted Therapy of Leukemias 2.0)
Mantle cell lymphoma (MCL) is a heterogeneous malignancy with a broad spectrum of clinical behavior from indolent to highly aggressive cases. Despite the fact that MCL remains in most cases incurable by currently applied immunochemotherapy, our increasing knowledge on the biology of MCL in the last two decades has led to the design, testing, and approval of several innovative agents that dramatically changed the treatment landscape for MCL patients. Most importantly, the implementation of new drugs and novel treatment algorithms into clinical practice has successfully translated into improved outcomes of MCL patients not only in the clinical trials, but also in real life. This review focuses on recent advances in our understanding of the pathogenesis of MCL, and provides a brief survey of currently used treatment options with special focus on mode of action of selected innovative anti-lymphoma molecules. Finally, it outlines future perspectives of patient management with progressive shift from generally applied immunotherapy toward risk-stratified, patient-tailored protocols that would implement innovative agents and/or procedures with the ultimate goal to eradicate the lymphoma and cure the patient.
View Full-Text
Keywords:
mantle cell lymphoma; cell cycle; B-cell receptor signaling
▼
Show Figures
Figure 1
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
MDPI and ACS Style
Klener, P. Advances in Molecular Biology and Targeted Therapy of Mantle Cell Lymphoma. Int. J. Mol. Sci. 2019, 20, 4417. https://doi.org/10.3390/ijms20184417
AMA Style
Klener P. Advances in Molecular Biology and Targeted Therapy of Mantle Cell Lymphoma. International Journal of Molecular Sciences. 2019; 20(18):4417. https://doi.org/10.3390/ijms20184417
Chicago/Turabian StyleKlener, Pavel. 2019. "Advances in Molecular Biology and Targeted Therapy of Mantle Cell Lymphoma" International Journal of Molecular Sciences 20, no. 18: 4417. https://doi.org/10.3390/ijms20184417
Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.
